Liver Cancer
Journey
Follow Ben on his individual Cancer Pathway
1Global burden of primary liver cancer in 2020 and predictions to 2040, 05, 2022. DOI:https://doi.org/10.1016/j.jhep.2022.08.021.
2Nature Reviews, Llovet et al, 2020. https://doi.org/10.1038/s41572-020-00240-3).
3MASLD = metabolic dysfunction-associated steatotic liver disease; HCC = hepatocellular carcinoma; ELF test = enhanced liver fibrosis; FIB-4 index = fibrosis 4
In the U.S., the ELF Test is indicated as a prognostic marker in conjunction with other laboratory findings and clinical assessments in patients with advanced fibrosis (F3 or F4) due to non-alcoholic steatohepatitis (NASH) to assess the likelihood of progression to cirrhosis and liver-related clinical events. In the U.S., the ELF Test is not for use in the diagnosis of NASH, for the staging of fibrosis, or for assessing progression to hepatocellular carcinoma.
In the U.S., the ELF Test is indicated as a prognostic marker in conjunction with other laboratory findings and clinical assessments in patients with advanced fibrosis (F3 or F4) due to non-alcoholic steatohepatitis (NASH) to assess the likelihood of progression to cirrhosis and liver-related clinical events. In the U.S., the ELF Test is not for use in the diagnosis of NASH, for the staging of fibrosis, or for assessing progression to hepatocellular carcinoma.
4UDFF = ultrasound derived fat fraction; Auto pSWE = automated point shear wave elastography; MASLD = metabolic dysfunction-associated steatotic liver disease; MASH = metabolic dysfunction-associated steatohepatitis, US = ultrasound; PDFF = proton density fat fraction
5MAGNETOM Flow. Platform with 60 cm bore size is not available for sale in the U.S.A. Its future availability cannot be ensured. MAGNETOM Flow. Platform with 70 cm bore size is currently under development and not commercially available. It is not for sale in the U.S.A. Its future availability cannot be ensured.
6Compressed Sensing GRASP-VIBE for other regions than liver is not for sale in the U.S.
7The information shown herein refers to products of 3rd party manufacturer’s and thus are in their regulatory responsibility. Please contact the 3rd party manufacturer for further information
8The NAEOTOM Alpha.Pro is pending 510(k) clearance, and is not yet commercially available in the United States and other countries.
9The products / features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.
10Syngo Carbon consists of several products which are (medical) devices in their own right. Some products are under development and not commercially available. Future availability cannot be ensured.
11eHealth Solutions consist of several products. eHealth Virtual Visit is manufactured by Siemens Healthineers, Erlangen, Germany. Products of eHealth Solutions are not intended for diagnostic purposes. The product offerings are not commercially available in all countries.